Pharmacokinetics of rifampicin PLGA nanoparticles compared to conventional formulation in healthy human volunteers
The PLGA nanoformulation of rifampicin showed difference in release profile compared to convention formulation over 24 hours. The plasma level of rifampicin in nanoformulation was significantly higher over 5 to 15 hours, and drug levels in plasma were detectable over five days but were below the limit of quantification (BLQ) of 250 ng/ml (Fig.7).
Significant difference in some pharmacokinetic parameters and PK/PD indices were found between nanoformulation of rifampicin as compared to conventional rifampicin (Table. 5 and 6).